Lakewood-Amedex Biotherapeutics, Inc. cash flow to debt ratio of -117.13% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Lakewood-Amedex Biotherapeutics, Inc. has insufficient data to evaluate this check.

Lakewood-Amedex Biotherapeutics, Inc. has insufficient data to evaluate this check.

Lakewood-Amedex Biotherapeutics, Inc. has insufficient data to evaluate this check.

Lakewood-Amedex Biotherapeutics, Inc. has negative EBITDA, making leverage ratio unreliable

Interest expense is not separately reported in Lakewood-Amedex Biotherapeutics, Inc.'s latest filing, so interest coverage cannot be calculated.

Lakewood-Amedex Biotherapeutics, Inc. has insufficient data to evaluate this check.

Lakewood-Amedex Biotherapeutics, Inc. has insufficient data to evaluate this check.

Lakewood-Amedex Biotherapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lakewood-Amedex Biotherapeutics, Inc.'s return on equity of 1.69K%, is higher than 15.00%, indicating good performance

Lakewood-Amedex Biotherapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lakewood-Amedex Biotherapeutics, Inc. has insufficient public price history to evaluate earnings stability.

Lakewood-Amedex Biotherapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Lakewood-Amedex Biotherapeutics, Inc. has negative free cash flow, indicating cash burn

Lakewood-Amedex Biotherapeutics, Inc.'s yearly earnings has increased 20.76% since last year from $-4.86M to $-3.85M, signaling increasing performance

Lakewood-Amedex Biotherapeutics, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -163.98% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Lakewood-Amedex Biotherapeutics, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Lakewood-Amedex Biotherapeutics, Inc. has insufficient public price history to evaluate revenue consistency.

Lakewood-Amedex Biotherapeutics, Inc. has insufficient public price history to evaluate ROE consistency.

Lakewood-Amedex Biotherapeutics, Inc. has insufficient data to evaluate this check.

Lakewood-Amedex Biotherapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lakewood-Amedex Biotherapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Lakewood-Amedex Biotherapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Lakewood-Amedex Biotherapeutics, Inc. has insufficient data to evaluate this check.

Lakewood-Amedex Biotherapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lakewood-Amedex Biotherapeutics, Inc. has a price-to-book ratio of 0.55x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Lakewood-Amedex Biotherapeutics, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue